A Study to Evaluate the Epidemiology of Estrogen Genotoxicity in Breast Cancer


About this study

The purpose of this study is to recruit 2000 incident cases of primary breast cancer in order to perform laboratory assays to measure frequencies of genetic polymorphisms for genes that encode enzymes involved in candidate gene pathways, including:  estrogen and catecholestrogen formation, bioactivation and inactivation, cellular proliferation and apoptosis, nuclear factor kappa-beta; to compare genotype frequencies for polymorphisms of genes in breast cancer cases and controls, and to evaluate possible interactions among common polymorphisms in candidate genes.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • No prior history of cancer (other than non-melanoma skin cancer).
  • Cases: diagnosed with breast cancer within 12 months of diagnosis.

Exclusion Criteria:


  • Unable to provide informed consent.
  • Unable to speak English.


Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Janet Olson, Ph.D.

Closed for enrollment

Contact information:

Janet Olson Ph.D.

(507) 284-9833


More information


Publications are currently not available

Mayo Clinic Footer